VolitionRx Limited (Volition)

VolitionRx Limited is a multinational epigenetics company dedicated to advancing the science of epigenetics to save lives and improve outcomes for both people and animals. The company focuses on the earlier detection and monitoring of life-altering diseases through innovative blood tests. Headquartered in Henderson, Nevada, U.S., VolitionRx conducts its primary research and development activities in Belgium, with additional offices and an innovation laboratory in the U.S., London, and Singapore.

Through its subsidiaries, VolitionRx develops and commercializes a range of simple, easy-to-use, and cost-effective blood tests. Key product lines include Nu.Q® Vet for animal cancer screening, Nu.Q® NETs for detecting diseases associated with NETosis such as sepsis, Nu.Q® Discover for nucleosome profiling, and Nu.Q® Cancer for predicting and monitoring cancer treatment response. The company also utilizes Capture-PCR and Capture-Seq technologies for isolating circulating tumor-derived DNA for early cancer detection, targeting both human and animal health markets.

In recent news, VolitionRx announced a collaboration with Sysmex Corporation in June 2026 to optimize its Nu.Q® NETs H3.1 assay for automated use on Sysmex's diagnostic platforms. The company reported a 300% increase in revenue for the first quarter of 2026, reaching $1 million. VolitionRx also filed a new patent in June 2026 for its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring and submitted a manuscript for its Nu.Q® Vet Cancer Test in Cats in May 2026. Cameron Reynolds serves as the President and CEO, with Dr. Martin Faulkes as the Executive Chairman. The company operates within the healthcare sector, specifically the Medical Devices & Instruments industry, aiming to address an estimated $3.8 billion total addressable market for its Nu.Q® NETs assay.